Xencor Inc. Stock
Price
Target price
€22.60
€22.60
-0.890%
-0.2
-0.890%
€32.58
06.05.24 / Tradegate
WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xencor Inc. Stock
Xencor Inc. shows a slight decrease today, losing -€0.200 (-0.890%) compared to yesterday.
We see a rather positive sentiment for Xencor Inc. with 10 Buy predictions and 1 Sell predictions.
As a result the target price of 32 € shows a positive potential of 41.59% compared to the current price of 22.6 € for Xencor Inc..
Pros and Cons of Xencor Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Cons
?
B****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | -0.890% | - | - | - | - | - | - |
| Ironwood Pharmaceuticals | 1.680% | -20.667% | -19.048% | -35.676% | -41.667% | -37.696% | - |
| Sage Therapeutics Inc. | 1.170% | -6.678% | -25.356% | -78.130% | -46.200% | -82.413% | - |
| Novocure Ltd | 2.260% | 29.648% | 61.587% | -72.975% | 35.552% | -86.890% | - |
Comments
Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at Wedbush from $34.00 to $36.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at BTIG Research from $56.00 to $38.00. They now have a "buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $32.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor Reports First Quarter 2024 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company